Your browser doesn't support javascript.
loading
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
Parikh, Ravi B; Adamson, Blythe J S; Khozin, Sean; Galsky, Matthew D; Baxi, Shrujal S; Cohen, Aaron; Mamtani, Ronac.
Affiliation
  • Parikh RB; Abramson Cancer Center, University of Pennsylvania, Philadelphia.
  • Adamson BJS; Flatiron Health, New York, New York.
  • Khozin S; US Food and Drug Administration, Silver Spring, Maryland.
  • Galsky MD; Tisch Cancer Institute, Icahn School of Medicine, New York, New York.
  • Baxi SS; Flatiron Health, New York, New York.
  • Cohen A; Flatiron Health, New York, New York.
  • Mamtani R; Abramson Cancer Center, University of Pennsylvania, Philadelphia.
JAMA ; 322(12): 1209-1211, 2019 09 24.
Article in En | MEDLINE | ID: mdl-31550019
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Drug Labeling / Drug Therapy / Programmed Cell Death 1 Receptor / Immunotherapy / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: JAMA Year: 2019 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Drug Labeling / Drug Therapy / Programmed Cell Death 1 Receptor / Immunotherapy / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: JAMA Year: 2019 Document type: Article Country of publication: United States